Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Seagen Inc.
Johnson & Johnson Enterprise Innovation Inc.
Janssen Research & Development, LLC
Genmab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Coherus Oncology, Inc.
AstraZeneca
VSPharmTech Co.,Ltd.
Hoffmann-La Roche
R-Pharm
R-Pharm
Merck Sharp & Dohme LLC
Inhibrx Biosciences, Inc
Incyte Corporation
MediLink Therapeutics (Suzhou) Co., Ltd.
Gilead Sciences
Rakuten Medical, Inc.
EMD Serono
EMD Serono
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
ALX Oncology Inc.
Merck Sharp & Dohme LLC
Iovance Biotherapeutics, Inc.
Privo Technologies
PhytoHealth Corporation
Akeso
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Akeso
Eurofarma Laboratorios S.A.
Akeso
ImmunityBio, Inc.
BeiGene
AstraZeneca
EpicentRx, Inc.
EpicentRx, Inc.
Taiho Pharmaceutical Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Shanghai Henlius Biotech
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
BioMimetix JV, LLC
Privo Technologies
CEL-SCI Corporation
Galera Therapeutics, Inc.
Jiangsu HengRui Medicine Co., Ltd.
Jiangsu HengRui Medicine Co., Ltd.